Hopitaux Universitaires Pitie Salpetriere
- Address
- lock Available on a paid plan
Hopitaux Universitaires Pitie Salpetriere - Comprehensive Academic Medical Research Center
Hopitaux Universitaires Pitie Salpetriere stands as a leading academic medical research center with extensive expertise across multiple therapeutic domains. The institution demonstrates particular strength in oncology, neurosciences, infectious diseases, and autoimmune disorders, conducting cutting-edge Phase II and III clinical trials that advance precision medicine approaches and innovative therapeutic combinations.
- Advanced oncology research spanning bladder cancer, hepatocellular carcinoma, glioblastoma, pancreatic adenocarcinoma, colorectal cancer, ovarian cancer, and hematologic malignancies including multiple myeloma, lymphomas, and leukemias
- Neuroscience investigations in neurodegenerative diseases (Alzheimer's disease, Huntington's disease, spinocerebellar ataxia, amyotrophic lateral sclerosis), cerebrovascular disorders (subarachnoid hemorrhage, ischemic stroke), and multiple sclerosis
- Infectious disease and immunology studies including HIV treatment optimization, viral infections post-transplantation, and therapeutic drug monitoring strategies
- Autoimmune and inflammatory conditions encompassing non-infectious uveitis, rheumatoid arthritis, giant cell arteritis, pulmonary sarcoidosis, and recurrent aphthous stomatitis
The center excels in pioneering immunotherapy combinations, targeted molecular therapies, and personalized treatment strategies based on biomarkers and therapeutic drug monitoring. Research protocols frequently incorporate advanced imaging modalities including PET-CT and MRI-guided interventions, alongside novel approaches in transplant immunology, radioimmunotherapy with agents like Lutathera, and maintenance therapy optimization. The institution's comprehensive portfolio reflects its commitment to translational research addressing unmet clinical needs across diverse patient populations, from solid organ transplant recipients to patients with rare genetic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 26 therapeutic areas and 15 of 346 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 313 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 67 by active trials.
lock +66 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +40 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopitaux Universitaires Pitie Salpetriere
lock Showing 1 of 201 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis | Cogent Biosciences Inc. | Phase II | Not Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 346 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Oxaliplatin | 16 | Unknown | 2014-12-23 | 2026-02-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.